Zealand Pharma to host a Capital Market Day and Site Visit

3/22/2011 2:00 AM EST

Zealand Pharma A/S
Investor News

Zealand Pharma to host a Capital Market Day and Site Visit



Investor News

No. 04/2011


                                        




           Zealand Pharma to host a Capital Market Day and Site Visit


                Wednesday, 6 April 2011 from 12:00 to 4:30pm CET.



Copenhagen, 22 March 2011 - Zealand Pharma (NASDAQ OMX: ZEAL), a Scandinavian
based biopharmaceutical company with a mature drug pipeline, including
lixisenatide, a diabetes product in late-stage Phase III development in
collaboration with sanofi-aventis, will host a capital market day and site
visit at its Copenhagen headquarters on Wednesday, 6 April 2011 from 12:00 to
16:30 CET. 

During the event, members of the Zealand Pharma management team will present
the business opportunity and model as well as the strategy of the company.
Focus will be on Zealand Pharma's pipeline of novel peptide drugs for better
treatment of selected metabolic (diabetes and obesity), gastro-intestinal and
cardiovascular diseases. 

As part of the programme for the day, Dr. Bernard Charbonnel, Chair of the
Department of Medicine at the Université de Nantes, will give a keynote
presentation on the outlook for diabetes treatment and the impact of GLP-1 and
new insulin treatments. 

An invitation with a detailed agenda of the day can be seen and downloaded from
the company's website under ‘'Investors'' (http://ir.zealandpharma.com). 

All presentations will be made in English and a webcast will be made available
on the company's website after the event. 




                                      # # #



For further information, or to receive a detailed agenda of the event, please
contact: 

Zealand Pharma

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate
Communications 

Tel: +45 8877 3689 or Mobile: +45 5060 3689,  



M:Communications

Mary-Jane Elliott / Emma Thompson / Amber Bielecka

Tel: +44 20 7920 2330









About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) Scandinavian based
biopharmaceutical company with a mature and growing clinical pipeline of
innovative peptide based drugs. The company's lead product candidate is a
once-daily GLP-1 in late-stage Phase III development for the treatment of Type
2 Diabetes in collaboration with sanofi-aventis. Zealand Pharma also has
several other collaboration and licensing partnerships, including a license
agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the
treatment of Radio and Chemotherapy-Induced Diarrhoea. 

Zealand Pharma has unique expertise in peptide discovery and optimization and
in the development of novel peptide drugs with favourable therapeutic
attributes. The company targets metabolic (diabetes and obesity),
gastrointestinal and cardiovascular diseases, where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high. All of Zealand Pharma's
product candidates have been identified through the company's own drug
discovery activities. The company is headquartered in Copenhagen and has
approximately 90 employees. For more information please visit
www.zealandpharma.com.